Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Sales | 5,602,000 | 6,046,600 | 6,147,900 | 6,252,800 | 5,839,200 |
| Cost of Goods | 1,197,900 | 1,321,700 | 1,338,100 | 1,228,000 | 1,180,100 |
| Gross Profit | 4,404,100 | 4,724,900 | 4,809,800 | 5,024,800 | 4,659,100 |
| Operating Expenses | 3,023,700 | 3,733,300 | 3,224,000 | 3,435,900 | 3,297,800 |
| Operating Income | 1,381,300 | 992,300 | 1,585,900 | 1,588,900 | 1,361,400 |
| Other Income | -46,000 | 49,500 | -83,400 | -57,600 | -87,500 |
| Pre-tax Income | 1,335,300 | 1,041,800 | 1,502,500 | 1,531,300 | 1,273,900 |
| Income Tax | 324,200 | 183,600 | 266,200 | 334,000 | 218,000 |
| Net Income Continuous | 1,011,100 | 858,200 | 1,236,300 | 1,197,300 | 1,055,900 |
| Net Income | $1,011,100 | $858,200 | $1,236,300 | $1,197,300 | $1,055,900 |
| EPS Basic Total Ops | 0.91 | 0.77 | 1.11 | 1.07 | 0.95 |
| EPS Basic Continuous Ops | 0.91 | 0.76 | 1.11 | 1.08 | 0.95 |
| EPS Diluted Total Ops | 0.91 | 0.77 | 1.11 | 1.07 | 0.95 |
| EPS Diluted Continuous Ops | 0.91 | 0.77 | 1.11 | 1.07 | 0.95 |
| EBITDA(a) | $1,767,200 | $1,311,200 | $1,944,100 | $1,944,500 | $1,702,300 |